Galmed Deferred Long Term Liab from 2010 to 2024
| GLMD Stock | USD 2.86 0.01 0.35% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 476.1 K | Current Value 423.2 K | Quarterly Volatility 29.7 K |
Check Galmed Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galmed Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 57.1 K, Interest Expense of 10.4 K or Selling General Administrative of 4.3 M, as well as many indicators such as Price To Sales Ratio of 1.1 K, Dividend Yield of 0.0 or PTB Ratio of 0.0919. Galmed financial statements analysis is a perfect complement when working with Galmed Pharmaceuticals Valuation or Volatility modules.
Galmed | Deferred Long Term Liab |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:Check out the analysis of Galmed Pharmaceuticals Correlation against competitors. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 69.72 | Return On Assets (0.29) | Return On Equity (0.53) |
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.